Ex-US FDA official to lead Hong Kong’s new medical products regulator
A Beijing-educated former official at the US federal drug regulator has been appointed to lead Hong Kong’s new medical products body, tasked with accelerating the clinical use of medicines and medical devices as part of a regulatory overhaul. Li Zili, who previously worked at the US Food and Drug Administration (FDA), would take up the post of controller for medical products regulation under the…
US FDA veteran Li Zili, a Beijing-educated medical professional, has been appointed to head Hong Kong's new medical products regulatory body. Li, who previously held positions at the FDA, will serve as controller for medical products regulation under the Hong Kong Department of Health for a three-year term starting October 20. The Centre for Medical Products Regulation, to be established later this year, aims to expedite the use of advanced medical products through proactive evaluation and speed up clinical applications.
Li's extensive experience in pharmaceutical regulation, global drug development, and leadership roles at multinational companies, including Janssen Pharmaceutical Companies of Johnson & Johnson, makes him an ideal candidate to build the new regulatory centre's capabilities. Hong Kong's director of health, Ronald Lam Man-kin, expressed confidence in Li's ability to rapidly and systematically strengthen the regulatory framework, praising his expertise in international medical product regulation and public health policy.
Written by urgent.news from South China Morning Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
